0000000000223344

AUTHOR

Francesco Boscia

0000-0002-5478-060x

showing 8 related works from this author

Enhanced depth imaging optical coherence tomography of the choroid in idiopathic macular hole: A cross-sectional prospective study.

2010

Purpose To determine the choroidal thickness in the macular area in patients with idiopathic macular hole in one eye and an unaffected fellow eye and in healthy controls. Design Cross-sectional, prospective study. Methods Twenty-two patients with a full-thickness unilateral idiopathic macular hole and 22 age- and sex-matched controls were recruited. Enhanced depth imaging optical coherence tomography images were obtained by using spectral-domain optical coherence tomography. The choroidal thickness was measured in the subfoveal area and 1000 μm and 2000 μm away from the fovea in the nasal and temporal regions. The diameter of the macular hole and the axial length were determined. Results Ch…

Malemedicine.medical_specialtygenetic structuresEye diseaseOptical coherence tomographyOphthalmologymedicineHumansProspective StudiesProspective cohort studyMacular holeAgedCross-Sectional StudieAged 80 and overmedicine.diagnostic_testbusiness.industryChoroidMiddle Agedmedicine.diseaseRetinal Perforationseye diseasesProspective StudieOphthalmologyAxial Length Eyemedicine.anatomical_structureCross-Sectional StudiesRetinal PerforationMaculopathyFemalesense organsEnhanced depth imagingChoroidbusinessTomography Optical CoherenceHumanRetinopathyAmerican journal of ophthalmology
researchProduct

Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat stu…

2020

Purpose: To report clinical outcomes of two different timings of intravitreal dexamethasone (DEX) implant administration for prevention of diabetic macular oedema (DME) worsening following cataract surgery. Methods: This multicentre, retrospective study included patients with DME who received an intravitreal DEX implant 1 month before cataract surgery, ‘precataract DEX’ group, or at the time of cataract surgery, ‘concomitant treatments’ group. Inclusion criteria were a follow-up ≥3 months and ophthalmological examination with optical coherence tomography (OCT) imaging at baseline (cataract surgery) and throughout follow-up. Anatomical improvement was considered to be a decrease in OCT centr…

MaleTime FactorsVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityDexamethasone0302 clinical medicinedexamethasone implantDrug Implantsdiabetescataract surgeryGeneral MedicineTreatment Outcomediabetic macular oedemaIntravitreal InjectionsFemalecataract surgery; dexamethasone implant; diabetes; diabetic macular oedemamedicine.symptomTomography Optical Coherencemedicine.drugmedicine.medical_specialtyCataract ExtractionCataractMacular Edema03 medical and health sciencesOphthalmologyDiabetes mellitusmedicineHumansAdverse effectGlucocorticoidsDexamethasoneAgedRetrospective StudiesDiabetic RetinopathySettore MED/30 - Malattie Apparato Visivobusiness.industryRetrospective cohort studyCataract surgerymedicine.diseaseeye diseasesOphthalmologydiabeteConcomitant030221 ophthalmology & optometryImplantbusiness030217 neurology & neurosurgeryFollow-Up StudiesActa Ophthalmologica
researchProduct

Efficacy of Three Different Prophylactic Treatments for Postoperative Nausea and Vomiting after Vitrectomy: A Randomized Clinical Trial

2019

Postoperative nausea and vomiting (PONV) after vitreoretinal surgery may potentially be associated with severe complications, such as suprachoroidal hemorrhage. The purpose of the present multicenter clinical trial (NCT02386059) was to assess the efficacy of three different prophylactic treatments for PONV after vitrectomy under local anesthesia. Patients undergoing primary vitrectomy were randomized to the control arm or to one of the treatment arms (4 mg ondansetron, 4 mg dexamethasone, combination of the two drugs). The primary outcome measure was the proportion of complete response (no nausea, no vomiting, no retching, and no use of antiemetic rescue medication) during 24 h after vitrec…

Nauseamedicine.drug_classvitrectomylcsh:Medicinepostoperative nausea and vomitingdexamethasoneArticlelaw.inventionOndansetron03 medical and health sciences0302 clinical medicineRandomized controlled trial030202 anesthesiologylawmedicineAntiemeticRetchingLocal anesthesiabusiness.industrylcsh:RGeneral MedicineondansetronAnesthesia030221 ophthalmology & optometryVomitingdexamethasone; ondansetron; postoperative nausea and vomiting; vitrectomymedicine.symptombusinessPostoperative nausea and vomitingmedicine.drug
researchProduct

Delayed Suprachoroidal Hemorrhage After Pars Plana Vitrectomy: Five-Year Results of a Retrospective Multicenter Cohort Study

2015

Purpose To determine the incidence, risk factors, and outcomes of delayed suprachoroidal hemorrhage after vitrectomy. Design Retrospective multicenter cohort study. Methods All consecutive patients who underwent primary vitrectomy, from January 2009 to December 2014, at 4 tertiary vitreoretinal centers in Italy were enrolled. Patient demographics and systemic, ophthalmic, operative, and postoperative data from all centers were extracted from the electronic record system using standardized data collection forms. All eyes that developed delayed suprachoroidal hemorrhage within 48 hours of the end of the vitrectomy were identified as the delayed suprachoroidal hemorrhage group; all other eyes …

Pars planaChoroid HemorrhageMalemedicine.medical_specialtyTime FactorsTime FactorFundus Oculimedicine.medical_treatmentVitrectomyPostoperative HemorrhageChoroid hemorrhageFollow-Up StudieRetrospective StudieRisk FactorsOphthalmologyVitrectomymedicineHumansFluorescein AngiographyAgedRetrospective Studiesmedicine.diagnostic_testbusiness.industryRisk FactorRetinal DetachmentRetinal detachmentRetrospective cohort studyOdds ratioMiddle AgedFluorescein angiographymedicine.diseaseSurgeryOphthalmologymedicine.anatomical_structureFemalebusinessHumanCohort studyFollow-Up Studies
researchProduct

Angioid streak-related choroidal neovascularization treated by intravitreal ranibizumab.

2010

PURPOSE The purpose of this study was to report the visual outcome of intravitreal therapy with ranibizumab of choroidal neovascularization secondary to angioid streaks after 1-year follow-up. METHODS Nine patients (age, 58 +/- 4 years; range, 53-65 years) were treated with off-label intravitreal injections of 0.3 mg ranibizumab. Primary outcomes were best-corrected visual acuity changes (Early Treatment Diabetic Retinopathy Study logarithm of the minimum angle of resolution and letters) and optical coherence tomography macular thickness changes. RESULTS Mean follow-up was 14 months (+/-2; range, 12-18 months). Mean visual acuity was 0.52 logarithm of the minimum angle of resolution and 30 …

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresVisual AcuitymonoclonalAngiogenesis InhibitorsAntibodies Monoclonal HumanizedLoading doseChoroidal neovascularization; male; treatment outcome; injections; middle aged; vascular endothelial growth factor a; female; vitreous body; humans; retreatment; visual acuity; angiogenesis inhibitors; aged; angioid streaks; antibodies monoclonalInjectionsNeovascularizationOptical coherence tomographyOphthalmologyRanibizumabMedicineantibodiesHumansANTI-VEGFAgedintravitreal ranibizumabmedicine.diagnostic_testbusiness.industrySettore MED/30 - Malattie Apparato VisivoAntibodies MonoclonalGeneral MedicineDiabetic retinopathyMiddle Agedmedicine.diseaseeye diseasesChoroidal NeovascularizationVitreous BodyOphthalmologyAngioid streaksChoroidal neovascularizationTreatment OutcomeRetreatmentAngioid StreaksFemalemedicine.symptomRanibizumabbusinessAngioid streak-related choroidal neovascularizationmedicine.drugRetina (Philadelphia, Pa.)
researchProduct

LATE-ONSET OCULAR HYPERTENSION AFTER VITRECTOMY: A Multicenter Study of 6,048 Eyes

2018

Purpose: To determine the incidence and risk factors for late-onset ocular hypertension (LOH) after vitrectomy. Methods: From the electronic medical records of consecutive patients who underwent primary vitrectomy, from January 2010 to December 2015, at 5 tertiary vitreoretinal centers in Italy, patient demographics, systemic, ophthalmic, operative, and postoperative data were drawn. Main outcome measure was the presence of LOH, defined as intraocular pressure >21 mmHg detected more than 2 months after vitrectomy on at least 2 consecutive visits. Results: Among 6,048 patients, LOH was found in 294 (4.9%) vitrectomized eyes and in 87 (1.4%) fellow eyes, (chi square; P < 0.001). Multiva…

MalePediatricsmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentMEDLINEOcular hypertensionVitrectomyLate onset01 natural sciences03 medical and health sciences0302 clinical medicineRetinal DiseasesRisk FactorsVitrectomyHumansMedicineIntraocular PressureAgedRetrospective Studiesbusiness.industryIncidenceMedical recordIncidence (epidemiology)Retrospective cohort studyGeneral Medicinemedicine.disease0104 chemical sciences010404 medicinal & biomolecular chemistryOphthalmologyItalyMulticenter study030221 ophthalmology & optometryFemaleOcular Hypertensionbusinesslate-onset ocular hypertensionFollow-Up Studies
researchProduct

Risk of Death Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: A Systematic Review and Meta-analysis.

2020

Importance Although intravitreal anti–vascular endothelial growth factor (VEGF) treatment represents the first-line therapy for many retinal diseases, the issue of their systemic safety is debatable. Objectives To assess whether intravitreal anti-VEGF therapy might be associated with increased risk of mortality and which variables are associated with the increase. Data Sources PubMed, MEDLINE, and Embase databases, the Cochrane Library, and ClinicalTrials.gov were systematically searched from inception to May 6, 2019. Study Selection Randomized clinical trials comparing intravitreal anti-VEGF treatment with control groups and with follow-up of at least 6 months were selected. Data Extractio…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyDatabases FactualMEDLINEAngiogenesis InhibitorsCochrane LibraryMacular Edemalaw.inventionRandomized controlled triallawFrequentist inferenceInternal medicineCause of DeathRetinal Vein OcclusionMedicineHumansanti-VEGF therapyrisk of mortality anti-vascular endothelial growth factor mortalityCause of deathOriginal InvestigationRandomized Controlled Trials as TopicDiabetic Retinopathybusiness.industryMortality rateOdds ratioChoroidal NeovascularizationOphthalmologyMeta-analysisIntravitreal InjectionsWet Macular DegenerationbusinessJAMA ophthalmology
researchProduct

Incidence and Risk Factors for Tractional Macular Detachment after Anti-Vascular Endothelial Growth Factor Agent Pretreatment before Vitrectomy for C…

2019

The study&rsquo

medicine.medical_specialtyYounger agegenetic structuresmedicine.medical_treatmentvitrectomyVitrectomytractional macular detachmentArticle03 medical and health sciences0302 clinical medicineOphthalmologymedicine030212 general & internal medicineanti-VEGF; proliferative diabetic retinopathy; tractional macular detachment; vitrectomyAnti vegfbusiness.industryPrimary vitrectomyIncidence (epidemiology)General MedicineDiabetic retinopathymedicine.diseaseeye diseasesMacular detachmentanti-VEGFVitreous hemorrhage030221 ophthalmology & optometrysense organsbusinessproliferative diabetic retinopathyJournal of Clinical Medicine
researchProduct